Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Celldex has key catalysts in 2023, says Cantor Fitzgerald » 08:06
12/28/22
12/28
08:06
12/28/22
08:06
CLDX

Celldex

$43.59 /

-0.405 (-0.92%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Celldex with a $55 price target as part of her "New Year's Countdown" of 10 stocks with 2023 catalysts that should be on investors' radar. Celldex's barzolvolimab has been one of the most followed clinical candidates in the space, and 2023 should bring updates across multiple indications, potentially starting in February, Kluska tells investors in a research note. She believes investors see opportunity for barzolvolimab beyond chronic spontaneous urticaria and chronic inducible urticaria.

ShowHide Related Items >><<
CLDX Celldex
$43.59 /

-0.405 (-0.92%)

CLDX Celldex
$43.59 /

-0.405 (-0.92%)

12/16/22 LifeSci Capital
Third Harmonic Bio downgraded to Market Perform at LifeSci Capital
12/15/22 Guggenheim
Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim
10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$43.59 /

-0.405 (-0.92%)

CLDX Celldex
$43.59 /

-0.405 (-0.92%)

CLDX Celldex
$43.59 /

-0.405 (-0.92%)

On The Fly
Sell these stocks now, proven algorithm says » 14:38
12/23/22
12/23
14:38
12/23/22
14:38
VERV

Verve Therapeutics

$18.27 /

-0.86 (-4.50%)

, EQX

Equinox Gold

$3.54 /

+0.03 (+0.85%)

, GH

Guardant Health

$28.08 /

-2.11 (-6.99%)

, TOST

Toast

$17.50 /

-0.15 (-0.85%)

, CCL

Carnival

$7.74 /

-0.14 (-1.78%)

, CLDX

Celldex

$43.95 /

-1.4 (-3.09%)

, GDS

GDS Holdings

$19.39 /

-0.63 (-3.15%)

, GME

GameStop

$20.38 /

+0.58 (+2.93%)

, SMR

Nuscale Power

$10.05 /

-0.015 (-0.15%)

, EXAS

Exact Sciences

$50.65 /

-2.49 (-4.69%)

Here are this week's…

ShowHide Related Items >><<
VERV Verve Therapeutics
$18.27 /

-0.86 (-4.50%)

TOST Toast
$17.50 /

-0.15 (-0.85%)

SMR Nuscale Power
$10.05 /

-0.015 (-0.15%)

GME GameStop
$20.38 /

+0.58 (+2.93%)

GH Guardant Health
$28.08 /

-2.11 (-6.99%)

EXAS Exact Sciences
$50.65 /

-2.49 (-4.69%)

EQX Equinox Gold
$3.54 /

+0.03 (+0.85%)

CLDX Celldex
$43.95 /

-1.4 (-3.09%)

CCL Carnival
$7.74 /

-0.14 (-1.78%)

VERV Verve Therapeutics
$18.27 /

-0.86 (-4.50%)

12/15/22 Goldman Sachs
Verve Therapeutics initiated with a Sell at Goldman Sachs
12/05/22 Stifel
Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
12/02/22 Guggenheim
Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
10/06/22 Credit Suisse
Verve Therapeutics initiated with a Neutral at Credit Suisse
EQX Equinox Gold
$3.54 /

+0.03 (+0.85%)

12/07/22 National Bank
Equinox Gold price target raised to C$5.50 from C$5 at National Bank
12/07/22 BMO Capital
Equinox Gold price target raised to C$6.50 from C$6 at BMO Capital
11/07/22 BMO Capital
Equinox Gold price target lowered to C$6 from C$7.50 at BMO Capital
11/04/22 National Bank
Equinox Gold price target lowered to C$4 from C$5 at National Bank
GH Guardant Health
$28.08 /

-2.11 (-6.99%)

12/16/22 Goldman Sachs
Goldman says Guardant selloff, Exact Science rally an overreaction
12/16/22 BofA
Guardant Health price target raised to $70 from $65 at BofA
12/16/22 Cowen
Guardant Health price target lowered to $70 from $83 at Cowen
12/16/22 Morgan Stanley
Guardant's 'optical miss' presents 'compelling' entry point, says Morgan Stanley
TOST Toast
$17.50 /

-0.15 (-0.85%)

12/16/22 Wells Fargo
Wells Fargo sees significant opportunity ahead for Toast
12/12/22 Mizuho
Fiserv price target lowered to $135 from $145 at Mizuho
11/29/22 Wolfe Research
Toast initiated with a Peer Perform at Wolfe Research
11/11/22 Needham
Toast price target raised to $32 from $27 at Needham
CCL Carnival
$7.74 /

-0.14 (-1.78%)

12/21/22 Stifel
Carnival's lack of full-year guidance shouldn't be concerning, says Stifel
12/15/22 Barclays
Carnival price target raised to $12 from $10 at Barclays
12/14/22 Stifel
Carnival price target raised to $18 at Stifel, would buy ahead of Q4 report
12/12/22 Credit Suisse
Credit Suisse keeps Outperform on Carnival, lowers price target to $19
CLDX Celldex
$43.95 /

-1.4 (-3.09%)

12/16/22 LifeSci Capital
Third Harmonic Bio downgraded to Market Perform at LifeSci Capital
12/15/22 Guggenheim
Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim
10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
GDS GDS Holdings
$19.39 /

-0.63 (-3.15%)

11/29/22 RBC Capital
GDS Holdings price target lowered to $15 from $22 at RBC Capital
11/23/22 Truist
GDS Holdings price target lowered to $50 from $75 at Truist
11/23/22 HSBC
GDS Holdings price target lowered to $36 from $39 at HSBC
08/26/22 RBC Capital
GDS Holdings downgraded to Sector Perform from Outperform at RBC Capital
GME GameStop
$20.38 /

+0.58 (+2.93%)

12/08/22 Wedbush
GameStop price target lowered to $5.30 from $6 at Wedbush
10/13/22 Jefferies
GameStop transferred with a Hold at Jefferies
08/16/22 B. Riley
B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell
07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
SMR Nuscale Power
$10.05 /

-0.015 (-0.15%)

10/25/22 UBS
Nuscale Power initiated with a Neutral at UBS
08/25/22 Wells Fargo
Nuscale Power initiated with an Equal Weight at Wells Fargo
08/18/22 Guggenheim
Guggenheim starts 'unique opportunity' Nuscale Power with Buy, $18 target
08/18/22 Guggenheim
Nuscale Power initiated with a Buy at Guggenheim
EXAS Exact Sciences
$50.65 /

-2.49 (-4.69%)

12/16/22 Jefferies
Guardant data missing expectations removes overhang on Exact, says Jefferies
11/14/22 Piper Sandler
Exact Sciences price target raised to $50 from $40 at Piper Sandler
11/07/22 Raymond James
Exact Sciences price target lowered to $60 from $70 at Raymond James
VERV Verve Therapeutics
$18.27 /

-0.86 (-4.50%)

TOST Toast
$17.50 /

-0.15 (-0.85%)

GME GameStop
$20.38 /

+0.58 (+2.93%)

GH Guardant Health
$28.08 /

-2.11 (-6.99%)

GDS GDS Holdings
$19.39 /

-0.63 (-3.15%)

EXAS Exact Sciences
$50.65 /

-2.49 (-4.69%)

EQX Equinox Gold
$3.54 /

+0.03 (+0.85%)

CLDX Celldex
$43.95 /

-1.4 (-3.09%)

CCL Carnival
$7.74 /

-0.14 (-1.78%)

  • 21
    Jul
  • 21
    Jul
GME GameStop
$20.38 /

+0.58 (+2.93%)

CCL Carnival
$7.74 /

-0.14 (-1.78%)

VERV Verve Therapeutics
$18.27 /

-0.86 (-4.50%)

TOST Toast
$17.50 /

-0.15 (-0.85%)

SMR Nuscale Power
$10.05 /

-0.015 (-0.15%)

GME GameStop
$20.38 /

+0.58 (+2.93%)

GH Guardant Health
$28.08 /

-2.11 (-6.99%)

GDS GDS Holdings
$19.39 /

-0.63 (-3.15%)

EXAS Exact Sciences
$50.65 /

-2.49 (-4.69%)

EQX Equinox Gold
$3.54 /

+0.03 (+0.85%)

CLDX Celldex
$43.95 /

-1.4 (-3.09%)

CCL Carnival
$7.74 /

-0.14 (-1.78%)

TOST Toast
$17.50 /

-0.15 (-0.85%)

SMR Nuscale Power
$10.05 /

-0.015 (-0.15%)

GME GameStop
$20.38 /

+0.58 (+2.93%)

GH Guardant Health
$28.08 /

-2.11 (-6.99%)

GDS GDS Holdings
$19.39 /

-0.63 (-3.15%)

EXAS Exact Sciences
$50.65 /

-2.49 (-4.69%)

EQX Equinox Gold
$3.54 /

+0.03 (+0.85%)

CLDX Celldex
$43.95 /

-1.4 (-3.09%)

CCL Carnival
$7.74 /

-0.14 (-1.78%)

Downgrade
Third Harmonic Bio downgraded to Market Perform at LifeSci Capital » 07:09
12/16/22
12/16
07:09
12/16/22
07:09
THRD

Third Harmonic Bio

$4.48 /

-15.24 (-77.28%)

, CLDX

Celldex

$44.32 /

+3.98 (+9.87%)

, ALLK

Allakos

$7.18 /

+0.18 (+2.57%)

LifeSci Capital analyst…

LifeSci Capital analyst Sam Slutsky downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed his prior price target after the company announced that it is discontinuing the Phase Ib chronic inducible urticaria study with THB001 following the observation of asymptomatic liver transaminitis in two patients. As a result of the "disappointing and unexpected" update, the competitive landscape for chronic urticaria has "become thinner," said Slutsky, who noted that both Celldex (CLDX) and Allakos (ALLK) traded up yesterday following the news.

ShowHide Related Items >><<
THRD Third Harmonic Bio
$4.48 /

-15.24 (-77.28%)

CLDX Celldex
$44.32 /

+3.98 (+9.87%)

ALLK Allakos
$7.18 /

+0.18 (+2.57%)

THRD Third Harmonic Bio
$4.48 /

-15.24 (-77.28%)

12/15/22 Morgan Stanley
Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation
12/15/22 Morgan Stanley
Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley
12/15/22 Guggenheim
Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim
10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
CLDX Celldex
$44.32 /

+3.98 (+9.87%)

07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
ALLK Allakos
$7.18 /

+0.18 (+2.57%)

09/12/22 Cantor Fitzgerald
Allakos price target lowered to $7 from $10 at Cantor Fitzgerald
09/12/22 SMBC Nikko
Allakos downgraded to Underperform from Neutral at SMBC Nikko
08/08/22 BofA
Allakos price target lowered to $4 from $5 at BofA
05/11/22 Barclays
Allakos price target lowered to $2.50 from $7 at Barclays
CLDX Celldex
$44.32 /

+3.98 (+9.87%)

ALLK Allakos
$7.18 /

+0.18 (+2.57%)

  • 19
    Sep
  • 15
    Sep
THRD Third Harmonic Bio
$4.48 /

-15.24 (-77.28%)

CLDX Celldex
$44.32 /

+3.98 (+9.87%)

ALLK Allakos
$7.18 /

+0.18 (+2.57%)

CLDX Celldex
$44.32 /

+3.98 (+9.87%)

Recommendations
Third Harmonic 'further behind' Celldex after discontinuation, says Guggenheim » 13:14
12/15/22
12/15
13:14
12/15/22
13:14
CLDX

Celldex

$44.39 /

+4.05 (+10.04%)

, THRD

Third Harmonic Bio

$4.17 /

-15.55 (-78.85%)

After Third Harmonic Bio…

After Third Harmonic Bio (THRD) announced that the company has decided to discontinue the ongoing Phase 1b study of its investigational drug candidate THB001 after observing asymptomatic liver transaminitis in two trial subjects, Guggenheim analyst Yatin Suneja said the news "puts them even further behind" competitor Celldex (CLDX), which has treated more than 120 patients to date with barzolvolimab with no reported cases of transaminitis. Suneja, who continues to like barzo's profile in chronic urticarias and sees Celldex as "the clear leader in the c-KIT space" with one less competitor, keeps a Buy rating on Celldex shares.

ShowHide Related Items >><<
THRD Third Harmonic Bio
$4.17 /

-15.55 (-78.85%)

CLDX Celldex
$44.39 /

+4.05 (+10.04%)

CLDX Celldex
$44.39 /

+4.05 (+10.04%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
THRD Third Harmonic Bio
$4.17 /

-15.55 (-78.85%)

10/10/22 Morgan Stanley
Morgan Stanley starts Third Harmonic Bio at Overweight on potential of THB001
10/10/22 Cowen
Cowen starts Third Harmonic at Outperform on blockbuster potential
10/10/22 Cowen
Third Harmonic Bio initiated with an Outperform at Cowen
CLDX Celldex
$44.39 /

+4.05 (+10.04%)

  • 15
    Sep
THRD Third Harmonic Bio
$4.17 /

-15.55 (-78.85%)

CLDX Celldex
$44.39 /

+4.05 (+10.04%)

CLDX Celldex
$44.39 /

+4.05 (+10.04%)

Conference/Events
Celldex to host conference call » 07:45
12/06/22
12/06
07:45
12/06/22
07:45
CLDX

Celldex

$36.70 /

-0.665 (-1.78%)

Conference call to…

Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

Hot Stocks
Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria » 06:06
12/06/22
12/06
06:06
12/06/22
06:06
CLDX

Celldex

$36.70 /

-0.665 (-1.78%)

Celldex announced new…

Celldex announced new data from the company's open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GALEN Global Urticaria Forum in Berlin. All 9 of 9 - 100% - cold urticaria patients who received a 1.5 mg/kg single full dose of barzolvolimab experienced a complete response as assessed by provocation testing, including 4 of 4 patients with omalizumab refractory disease. This cohort was added to the Phase 1b trial in patients with chronic inducible urticaria after Celldex previously reported a 95% complete response rate in July 2021 in patients with antihistamine-refractory cold urticaria and symptomatic dermographism who received a single 3.0 mg/kg dose of barzolvolimab. The company also added an optional long term follow up evaluation for the initial cohorts of patients treated at 3.0 mg/kg beyond the original 12 week follow up period out to 36 weeks and confirmed that barzolvolimab-induced response and mast cell suppression are durable and linked. A randomized, double-blind, placebo-controlled, multi-dose Phase 2 subcutaneous study of barzolvolimab is currently enrolling patients with both cold urticaria and symptomatic dermographism.

ShowHide Related Items >><<
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

Conference/Events
Celldex to host conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
CLDX

Celldex

$36.70 /

-0.665 (-1.78%)

Conference call to…

Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

Conference/Events
Celldex to host conference call » 17:24
12/05/22
12/05
17:24
12/05/22
17:24
CLDX

Celldex

$36.70 /

-0.665 (-1.78%)

Conference call to…

Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

CLDX Celldex
$36.70 /

-0.665 (-1.78%)

On The Fly
Sell these stocks now, proven algorithm says » 16:18
11/18/22
11/18
16:18
11/18/22
16:18
WYNN

Wynn Resorts

$75.99 /

-1.96 (-2.51%)

, SAVA

Cassava Sciences

$33.31 /

-1.25 (-3.62%)

, AFRM

Affirm

$13.52 /

-1.06 (-7.27%)

, FREY

Freyr Battery

$13.76 /

-0.82 (-5.62%)

, INDI

Indie Semiconductor

$7.68 /

+0.945 (+14.03%)

, SMR

Nuscale Power

$11.14 /

+0.09 (+0.81%)

, DDD

3D Systems

$9.79 /

-0.23 (-2.30%)

, PSFE

Paysafe

$1.52 /

-0.1 (-6.17%)

, BEAM

Beam Therapeutics

$46.90 /

-0.46 (-0.97%)

, LFG

Archaea Energy

$25.87 /

+0.01 (+0.04%)

, MNDY

Monday.com

$96.90 /

-3.385 (-3.38%)

, OTLY

Oatly Group

$1.96 /

+0.075 (+3.98%)

, ZNTL

Zentalis

$22.23 /

+1.14 (+5.41%)

, INBX

Inhibrx

$28.97 /

-0.215 (-0.74%)

, ACVA

ACV Auctions

$7.99 /

-0.665 (-7.69%)

, CLDX

Celldex

$34.68 /

+0.42 (+1.23%)

, PCT

PureCycle Technologies

$6.26 /

-0.045 (-0.71%)

, BILI

Bilibili

$14.70 /

-1.095 (-6.93%)

, COMP

Compass

$2.80 /

-0.14 (-4.76%)

, NYMT

New York Mortgage

$2.75 /

+0.045 (+1.66%)

, RCL

Royal Caribbean

$58.74 /

+0.91 (+1.57%)

, U

Unity

$34.67 /

+0.825 (+2.44%)

, WRBY

Warby Parker

$16.11 /

-0.385 (-2.33%)

, GME

GameStop

$27.61 /

-0.13 (-0.47%)

, PL

Planet Labs

$5.11 /

-0.005 (-0.10%)

, CGC

Canopy Growth

$3.70 /

-0.415 (-10.09%)

Here are this week's…

ShowHide Related Items >><<
ZNTL Zentalis
$22.23 /

+1.14 (+5.41%)

WYNN Wynn Resorts
$75.99 /

-1.96 (-2.51%)

WRBY Warby Parker
$16.11 /

-0.385 (-2.33%)

U Unity
$34.67 /

+0.825 (+2.44%)

SMR Nuscale Power
$11.14 /

+0.09 (+0.81%)

SAVA Cassava Sciences
$33.31 /

-1.25 (-3.62%)

RCL Royal Caribbean
$58.74 /

+0.91 (+1.57%)

PSFE Paysafe
$1.52 /

-0.1 (-6.17%)

PL Planet Labs
$5.11 /

-0.005 (-0.10%)

PCT PureCycle Technologies
$6.26 /

-0.045 (-0.71%)

OTLY Oatly Group
$1.96 /

+0.075 (+3.98%)

NYMT New York Mortgage
$2.75 /

+0.045 (+1.66%)

MNDY Monday.com
$96.90 /

-3.385 (-3.38%)

LFG Archaea Energy
$25.87 /

+0.01 (+0.04%)

INDI Indie Semiconductor
$7.68 /

+0.945 (+14.03%)

INBX Inhibrx
$28.97 /

-0.215 (-0.74%)

GME GameStop
$27.61 /

-0.13 (-0.47%)

FREY Freyr Battery
$13.76 /

-0.82 (-5.62%)

DDD 3D Systems
$9.79 /

-0.23 (-2.30%)

COMP Compass
$2.80 /

-0.14 (-4.76%)

CLDX Celldex
$34.68 /

+0.42 (+1.23%)

CGC Canopy Growth
$3.70 /

-0.415 (-10.09%)

BILI Bilibili
$14.70 /

-1.095 (-6.93%)

BEAM Beam Therapeutics
$46.90 /

-0.46 (-0.97%)

AFRM Affirm
$13.52 /

-1.06 (-7.27%)

ACVA ACV Auctions
$7.99 /

-0.665 (-7.69%)

WYNN Wynn Resorts
$75.99 /

-1.96 (-2.51%)

10/31/22 Gordon Haskett
Gordon Haskett wonders if 'more going on' as Fertitta takes stake in Wynn
10/17/22 Barclays
Wynn Resorts price target lowered to $70 from $71 at Barclays
09/26/22 Jefferies
Wynn Resorts upgraded to Buy at Jefferies as Macau plans to resume visitation
09/26/22 Jefferies
Las Vegas Sands upgraded to Buy at Jefferies as Macau plans to resume visitation
SAVA Cassava Sciences
$33.31 /

-1.25 (-3.62%)

11/16/22 B. Riley
Cassava Sciences downgraded to Neutral at B. Riley amid limited disclosures
11/16/22 B. Riley
Cassava Sciences downgraded to Neutral from Buy at B. Riley
11/08/22 Univest Securities
Cassava Sciences price target raised to $12 from $8 at Univest Securities
08/11/22 B. Riley
Cassava Sciences price target lowered to $44 from $58 at B. Riley
AFRM Affirm
$13.52 /

-1.06 (-7.27%)

11/10/22 DA Davidson
Affirm price target lowered to $32 from $50 at DA Davidson
11/10/22 Barclays
Affirm price target lowered to $16 from $29 at Barclays
11/09/22 Jefferies
Affirm price target lowered to $12 from $15 at Jefferies
11/09/22 Truist
Affirm price target lowered to $21 from $30 at Truist
FREY Freyr Battery
$13.76 /

-0.82 (-5.62%)

10/31/22 Cowen
Cowen starts Freyr Battery at Outperform, sees 'less technology risk'
10/31/22 Cowen
Freyr Battery initiated with an Outperform at Cowen
09/21/22 Morgan Stanley
Freyr Battery price target raised to $26, named a 'Top Pick' at Morgan Stanley
09/01/22 BTIG
Freyr Battery price target raised to $25 from $20 at BTIG
INDI Indie Semiconductor
$7.68 /

+0.945 (+14.03%)

07/20/22 Deutsche Bank
Indie Semiconductor price target lowered to $10 from $11 at Deutsche Bank
06/15/22 B. Riley
B. Riley downgrades eight semi stocks on 'demand destruction risk'
06/15/22 B. Riley
Indie Semiconductor downgraded to Neutral from Buy at B. Riley
05/13/22 B. Riley
Indie Semiconductor price target lowered to $9 from $15 at B. Riley
SMR Nuscale Power
$11.14 /

+0.09 (+0.81%)

10/25/22 UBS
Nuscale Power initiated with a Neutral at UBS
08/25/22 Wells Fargo
Nuscale Power initiated with an Equal Weight at Wells Fargo
08/18/22 Guggenheim
Guggenheim starts 'unique opportunity' Nuscale Power with Buy, $18 target
08/18/22 Guggenheim
Nuscale Power initiated with a Buy at Guggenheim
DDD 3D Systems
$9.79 /

-0.23 (-2.30%)

08/16/22 Credit Suisse
3D Systems initiated with an Underperform at Credit Suisse
05/11/22 Craig-Hallum
3D Systems price target lowered to $10 from $18 at Craig-Hallum
05/10/22 BofA
3D Systems price target lowered to $12 from $23 at BofA
03/01/22 Craig-Hallum
3D Systems price target lowered to $18 from $33 at Craig-Hallum
PSFE Paysafe
$1.52 /

-0.1 (-6.17%)

08/31/22 Susquehanna
Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see'
08/31/22 Susquehanna
Paysafe downgraded to Neutral from Positive at Susquehanna
08/11/22 Credit Suisse
Paysafe downgraded to Underperform from Neutral at Credit Suisse
08/10/22 RBC Capital
Paysafe downgraded to Sector Perform from Outperform at RBC Capital
BEAM Beam Therapeutics
$46.90 /

-0.46 (-0.97%)

11/08/22 Credit Suisse
Beam Therapeutics price target lowered to $53 from $65 at Credit Suisse
08/10/22 Barclays
Beam Therapeutics price target raised to $60 from $38 at Barclays
07/18/22 BMO Capital
Beam Therapeutics price target raised to $61 from $41 at BMO Capital
06/16/22 BMO Capital
Beam Therapeutics initiated with a Market Perform at BMO Capital
LFG Archaea Energy
$25.87 /

+0.01 (+0.04%)

11/14/22 Wells Fargo
Archaea Energy downgraded to Equal Weight from Overweight at Wells Fargo
10/04/22 Wells Fargo
Archaea Energy initiated with an Overweight at Wells Fargo
06/17/22 Barclays
Barclays starts Archaea Energy at Overweight on 'vast' growth potential
06/17/22 Barclays
Archaea Energy initiated with an Overweight at Barclays
MNDY Monday.com
$96.90 /

-3.385 (-3.38%)

11/15/22 Credit Suisse
Monday.com price target lowered to $140 from $180 at Credit Suisse
11/15/22 Citi
Monday.com price target raised to $138 from $135 at Citi
11/15/22 Canaccord
Monday.com price target lowered to $120 from $165 at Canaccord
10/21/22 Citi
Monday.com price target lowered to $135 from $156 at Citi
OTLY Oatly Group
$1.96 /

+0.075 (+3.98%)

11/16/22 RBC Capital
Oatly Group price target lowered to $7 from $8 at RBC Capital
11/16/22 Mizuho
Oatly Group price target lowered to $2.50 from $3.50 at Mizuho
09/13/22 Credit Suisse
Oatly Group downgraded to Neutral from Outperform at Credit Suisse
08/03/22 RBC Capital
Oatly Group price target lowered to $9 from $14 at RBC Capital
ZNTL Zentalis
$22.23 /

+1.14 (+5.41%)

11/14/22 Wedbush
Zentalis price target lowered to $32 from $51 at Wedbush
11/14/22 Wells Fargo
Zentalis price target lowered to $46 from $52 at Wells Fargo
11/10/22 Oppenheimer
Zentalis price target lowered to $50 from $80 at Oppenheimer
08/10/22 SVB Securities
Zentalis price target lowered to $42 from $67 at SVB Securities
INBX Inhibrx
$28.97 /

-0.215 (-0.74%)

10/05/22 Evercore ISI
Inhibrx price target raised to $60 from $54 at Evercore ISI
08/09/22 Credit Suisse
Inhibrx price target lowered to $48 from $53 at Credit Suisse
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
03/15/22 SMBC Nikko
Inhibrx initiated with an Outperform at SMBC Nikko
ACVA ACV Auctions
$7.99 /

-0.665 (-7.69%)

11/10/22 Citi
ACV Auctions price target lowered to $11 from $13 at Citi
11/10/22 Canaccord
ACV Auctions price target lowered to $12 from $18 at Canaccord
10/06/22 Jefferies
ACV Auctions price target lowered to $15 from $17 at Jefferies
06/30/22 JMP Securities
ACV Auctions price target lowered to $10 from $20 at JMP Securities
CLDX Celldex
$34.68 /

+0.42 (+1.23%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
PCT PureCycle Technologies
$6.26 /

-0.045 (-0.71%)

11/11/22 Cowen
PureCycle Technologies price target lowered to $11 from $15 at Cowen
09/15/22 Stifel
PureCycle Technologies initiated with a Buy at Stifel
08/15/22 Cowen
PureCycle Technologies price target lowered to $15 from $17 at Cowen
03/10/22 Craig-Hallum
PureCycle Technologies price target lowered to $18 from $26 at Craig-Hallum
BILI Bilibili
$14.70 /

-1.095 (-6.93%)

11/02/22 BofA
Bilibili downgraded to Neutral at BofA on 'challenging' monetization outlook
11/02/22 BofA
Bilibili downgraded to Neutral from Buy at BofA
10/28/22 Barclays
Bilibili price target lowered to $13 from $21 at Barclays
10/27/22 Citi
Bilibili downgraded to Neutral at Citi due to uncertainty over growth, profit
COMP Compass
$2.80 /

-0.14 (-4.76%)

09/01/22 Needham
Needham says Compass is 'preferred way' to play difficult real estate market
08/16/22 Barclays
Compass price target lowered to $5 from $7 at Barclays
07/21/22 Morgan Stanley
Compass downgraded to Equal Weight from Overweight at Morgan Stanley
05/16/22 Oppenheimer
Compass price target lowered to $9 from $14 at Oppenheimer
NYMT New York Mortgage
$2.75 /

+0.045 (+1.66%)

10/25/22 B. Riley
New York Mortgage price target lowered to $5 from $5.50 at B. Riley
07/17/22 Barclays
New York Mortgage price target lowered to $3 from $3.50 at Barclays
07/17/22 Keefe Bruyette
New York Mortgage downgraded to Market Perform at Keefe Bruyette
04/27/22 Barclays
New York Mortgage price target lowered to $3.50 from $4 at Barclays
RCL Royal Caribbean
$58.74 /

+0.91 (+1.57%)

11/17/22 Credit Suisse
Norwegian Cruise downgraded to Underperform from Outperform at Credit Suisse
11/14/22 UBS
Royal Caribbean price target raised to $76 from $56 at UBS
10/21/22 Tigress Financial
Royal Caribbean shares have upside to $80, says Tigress Financial
10/12/22 UBS
Royal Caribbean price target lowered to $56 from $65 at UBS
U Unity
$34.67 /

+0.825 (+2.44%)

11/17/22 Stifel
Unity price target raised to $40 from $30 at Stifel
11/15/22 Goldman Sachs
Unity reinstated with a Neutral at Goldman Sachs
11/10/22 DA Davidson
Unity price target lowered to $40 from $60 at DA Davidson
11/10/22 Oppenheimer
Unity price target lowered to $28 from $60 at Oppenheimer
WRBY Warby Parker
$16.11 /

-0.385 (-2.33%)

11/11/22 Baird
Warby Parker price target lowered to $23 from $25 at Baird
11/11/22 Citi
Warby Parker price target lowered to $26 from $29 at Citi
07/22/22 Piper Sandler
Warby Parker initiated with an Overweight at Piper Sandler
07/21/22 Goldman Sachs
Warby Parker price target lowered to $12 from $16 at Goldman Sachs
GME GameStop
$27.61 /

-0.13 (-0.47%)

10/13/22 Jefferies
GameStop transferred with a Hold at Jefferies
08/16/22 B. Riley
B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell
07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
05/26/22 Wedbush
Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns
PL Planet Labs
$5.11 /

-0.005 (-0.10%)

11/08/22 Deutsche Bank
Planet Labs initiated with a Buy at Deutsche Bank
09/13/22 Needham
Planet Labs price target raised to $9 from $8 at Needham
06/15/22 Craig-Hallum
Planet Labs price target lowered to $10 from $15 at Craig-Hallum
06/15/22 Needham
Planet Labs price target lowered to $8.00 from $10.50 at Needham
CGC Canopy Growth
$3.70 /

-0.415 (-10.09%)

11/09/22 Bernstein
Two more states legalize cannabis, $3B added to TAM, says Bernstein
11/07/22 Canaccord
Canopy Growth price target raised to C$5 from C$4.25 at Canaccord
11/01/22 Bernstein
Bernstein starts Canopy Growth at Underperform, sees equity raise
11/01/22 Bernstein
Canopy Growth initiated with an Underperform at Bernstein
ZNTL Zentalis
$22.23 /

+1.14 (+5.41%)

WYNN Wynn Resorts
$75.99 /

-1.96 (-2.51%)

WRBY Warby Parker
$16.11 /

-0.385 (-2.33%)

U Unity
$34.67 /

+0.825 (+2.44%)

SMR Nuscale Power
$11.14 /

+0.09 (+0.81%)

SAVA Cassava Sciences
$33.31 /

-1.25 (-3.62%)

RCL Royal Caribbean
$58.74 /

+0.91 (+1.57%)

PSFE Paysafe
$1.52 /

-0.1 (-6.17%)

PL Planet Labs
$5.11 /

-0.005 (-0.10%)

PCT PureCycle Technologies
$6.26 /

-0.045 (-0.71%)

OTLY Oatly Group
$1.96 /

+0.075 (+3.98%)

NYMT New York Mortgage
$2.75 /

+0.045 (+1.66%)

MNDY Monday.com
$96.90 /

-3.385 (-3.38%)

LFG Archaea Energy
$25.87 /

+0.01 (+0.04%)

INDI Indie Semiconductor
$7.68 /

+0.945 (+14.03%)

INBX Inhibrx
$28.97 /

-0.215 (-0.74%)

GME GameStop
$27.61 /

-0.13 (-0.47%)

FREY Freyr Battery
$13.76 /

-0.82 (-5.62%)

DDD 3D Systems
$9.79 /

-0.23 (-2.30%)

COMP Compass
$2.80 /

-0.14 (-4.76%)

CLDX Celldex
$34.68 /

+0.42 (+1.23%)

CGC Canopy Growth
$3.70 /

-0.415 (-10.09%)

BILI Bilibili
$14.70 /

-1.095 (-6.93%)

BEAM Beam Therapeutics
$46.90 /

-0.46 (-0.97%)

AFRM Affirm
$13.52 /

-1.06 (-7.27%)

ACVA ACV Auctions
$7.99 /

-0.665 (-7.69%)

  • 16
    May
  • 23
    Mar
WYNN Wynn Resorts
$75.99 /

-1.96 (-2.51%)

WRBY Warby Parker
$16.11 /

-0.385 (-2.33%)

U Unity
$34.67 /

+0.825 (+2.44%)

SAVA Cassava Sciences
$33.31 /

-1.25 (-3.62%)

RCL Royal Caribbean
$58.74 /

+0.91 (+1.57%)

OTLY Oatly Group
$1.96 /

+0.075 (+3.98%)

GME GameStop
$27.61 /

-0.13 (-0.47%)

COMP Compass
$2.80 /

-0.14 (-4.76%)

BILI Bilibili
$14.70 /

-1.095 (-6.93%)

AFRM Affirm
$13.52 /

-1.06 (-7.27%)

ZNTL Zentalis
$22.23 /

+1.14 (+5.41%)

WYNN Wynn Resorts
$75.99 /

-1.96 (-2.51%)

WRBY Warby Parker
$16.11 /

-0.385 (-2.33%)

U Unity
$34.67 /

+0.825 (+2.44%)

SMR Nuscale Power
$11.14 /

+0.09 (+0.81%)

SAVA Cassava Sciences
$33.31 /

-1.25 (-3.62%)

RCL Royal Caribbean
$58.74 /

+0.91 (+1.57%)

PSFE Paysafe
$1.52 /

-0.1 (-6.17%)

PL Planet Labs
$5.11 /

-0.005 (-0.10%)

PCT PureCycle Technologies
$6.26 /

-0.045 (-0.71%)

OTLY Oatly Group
$1.96 /

+0.075 (+3.98%)

NYMT New York Mortgage
$2.75 /

+0.045 (+1.66%)

MNDY Monday.com
$96.90 /

-3.385 (-3.38%)

LFG Archaea Energy
$25.87 /

+0.01 (+0.04%)

INDI Indie Semiconductor
$7.68 /

+0.945 (+14.03%)

INBX Inhibrx
$28.97 /

-0.215 (-0.74%)

GME GameStop
$27.61 /

-0.13 (-0.47%)

FREY Freyr Battery
$13.76 /

-0.82 (-5.62%)

DDD 3D Systems
$9.79 /

-0.23 (-2.30%)

COMP Compass
$2.80 /

-0.14 (-4.76%)

CLDX Celldex
$34.68 /

+0.42 (+1.23%)

CGC Canopy Growth
$3.70 /

-0.415 (-10.09%)

BILI Bilibili
$14.70 /

-1.095 (-6.93%)

BEAM Beam Therapeutics
$46.90 /

-0.46 (-0.97%)

AFRM Affirm
$13.52 /

-1.06 (-7.27%)

ACVA ACV Auctions
$7.99 /

-0.665 (-7.69%)

WYNN Wynn Resorts
$75.99 /

-1.96 (-2.51%)

WRBY Warby Parker
$16.11 /

-0.385 (-2.33%)

U Unity
$34.67 /

+0.825 (+2.44%)

SMR Nuscale Power
$11.14 /

+0.09 (+0.81%)

SAVA Cassava Sciences
$33.31 /

-1.25 (-3.62%)

RCL Royal Caribbean
$58.74 /

+0.91 (+1.57%)

PL Planet Labs
$5.11 /

-0.005 (-0.10%)

PCT PureCycle Technologies
$6.26 /

-0.045 (-0.71%)

OTLY Oatly Group
$1.96 /

+0.075 (+3.98%)

MNDY Monday.com
$96.90 /

-3.385 (-3.38%)

LFG Archaea Energy
$25.87 /

+0.01 (+0.04%)

GME GameStop
$27.61 /

-0.13 (-0.47%)

FREY Freyr Battery
$13.76 /

-0.82 (-5.62%)

CLDX Celldex
$34.68 /

+0.42 (+1.23%)

CGC Canopy Growth
$3.70 /

-0.415 (-10.09%)

BILI Bilibili
$14.70 /

-1.095 (-6.93%)

AFRM Affirm
$13.52 /

-1.06 (-7.27%)

COMP Compass
$2.80 /

-0.14 (-4.76%)

Hot Stocks
Celldex sees cash, equivalents sufficient to meet requirements through 2025  16:13
11/09/22
11/09
16:13
11/09/22
16:13
CLDX

Celldex

$32.62 /

-1.85 (-5.37%)

 
ShowHide Related Items >><<
CLDX Celldex
$32.62 /

-1.85 (-5.37%)

CLDX Celldex
$32.62 /

-1.85 (-5.37%)

10/10/22 Jefferies
Third Harmonic Bio initiated with a Buy at Jefferies
07/01/22 H.C. Wainwright
Celldex price target raised to $73 from $60 at H.C. Wainwright
CLDX Celldex
$32.62 /

-1.85 (-5.37%)

CLDX Celldex
$32.62 /

-1.85 (-5.37%)

CLDX Celldex
$32.62 /

-1.85 (-5.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.